Long Term Hypertension Leads to Glaucoma and Brinzolamide is a Viable Treatment Option

Long Term Hypertension Leads to Glaucoma and Brinzolamide is a Viable Treatment Option

human eye glaucoma

A new study published in the January 2015 Investigative Ophthalmology & Visual Science has shared alarming news regarding patients who suffer from long-term or chronic hypertension. Information gleaned from studies has revealed that people who are diagnosed with hypertension and who do not treat their condition are at a heightened risk for glaucoma. Ophthalmologists and optometrists are advised by many experts to consider their patients’ blood pressure, as well as their intraocular eye pressure when determining the use of both pressure lowering eye drops and potential blood pressure medication recommendations. Brinzolamide, known as the brand name drug Azopt, which is marketed by Alcon, is an effectual therapy for lowering intraocular pressure in patients with either high eye pressure or diagnosed open-angle glaucoma. Brinzolamide ophthalmic suspension 1% works by reducing the production of fluid in the eye, leading to better drainage and lowered pressure. The ability of Brinzolamide to reduce fluid retention also aids the eye in the overall reduction of nerve damage and vision loss due to developing or diagnosed glaucoma.

Adverse effects from Brinzolamide are extremely uncommon. Side effects reported include a mild taste perversion and slight blurriness in vision. The recommended dose of Brinzolamide is one drop in each affected eye, three times daily. Patients with contact lenses are not exempt from using Brinzolamide, however it is suggested that at least 15 minutes pass after the administration of the eye drop dosage before placing contacts back in. The drops should never be administered with contact lenses in the eye. Additionally, if other eye drops are being administered there should be at least a 10 minute waiting period before or after the administration of Brinzolamide.


Clinical studies, pre and post marketing, have shown an average 15 percent reduction in intraocular pressure (IOP) in patients who are dosed with Brinzolamide as monotherapy. As a leading cause of blindness worldwide, Glaucoma is a serious issue for a plethora of patients. The new data gleaned, which suggests hypertension as a clear risk factor for glaucoma is concerning to practitioners, especially with the uptick in hypertension in younger adults around the globe. The obesity crisis worldwide has led many adults, both young and old to conditions like hypertension, due to poor eating habits and a lack of regular exercise. The need for greater options for these patients to prevent and treat glaucoma is abundantly clear. LGM Pharma can assist clients as a supplier/distributor of the API Brinzolamide, CAS #138890-62-7 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service